Illumina (NASDAQ:ILMN) Stock Price Down 4.8% – Time to Sell?

Shares of Illumina, Inc. (NASDAQ:ILMN) were down 4.8% during mid-day trading on Thursday . The company traded as low as $131.38 and last traded at $133.60. Approximately 562,098 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 1,570,429 shares. The stock had previously closed at $140.36.

Analyst Ratings Changes

A number of research firms recently commented on ILMN. Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Stephens lifted their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Hsbc Global Res upgraded Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Morgan Stanley reduced their price objective on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and an average target price of $165.63.

Illumina Price Performance

The company has a fifty day simple moving average of $138.93 and a two-hundred day simple moving average of $134.46. The stock has a market capitalization of $21.60 billion, a price-to-earnings ratio of -13.68 and a beta of 1.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.33 earnings per share. As a group, equities research analysts expect that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Institutional Trading of Illumina

Several large investors have recently made changes to their positions in ILMN. Versant Capital Management Inc lifted its stake in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Private Trust Co. NA lifted its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in Illumina in the third quarter valued at about $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.